Clinical Trials Logo

Zellweger Syndrome clinical trials

View clinical trials related to Zellweger Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03856866 Completed - Zellweger Syndrome Clinical Trials

Hydroxychloroquine Administration for Reduction of Pexophagy

HARP
Start date: January 11, 2019
Phase: Phase 2
Study type: Interventional

A series of N-of-1, crossover, randomized, placebo-controlled, double-blinded trial. Hydroxychloroquine (HCQ) and a crossover to placebo (order is randomized and blinded) will be administered in liquid suspension for 84 days (12 weeks) each with an 84 day washout in between. We hypothesize that HCQ will reduce peroxisomal turnover, which will arrest ongoing injury in PBDs caused by PEX1, PEX6 or PEX26.

NCT ID: NCT03440905 Completed - Zellweger Spectrum Clinical Trials

Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders

Start date: January 29, 2018
Phase:
Study type: Observational

The purpose of this study is to characterize the symptoms of Zellweger Spectrum Disorder (ZSD) and related peroxisome disorders, and to assess the quality of life of family caregivers (parents, stepparents, legal guardians) of patients diagnosed with ZSD or a related peroxisome disorder. All family caregivers of patients enrolled in the Rare Diseases Clinical Research Network (RDCRN) Contact Registry who are diagnosed with ZSD or a related peroxisome disorder will be invited via email to participate in this study.

NCT ID: NCT00007020 Completed - Cholestasis Clinical Trials

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

Start date: January 1992
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid